NasdaqGS:KNSABiotechs
Assessing Kiniksa Pharmaceuticals (KNSA) Valuation After Strong Q1 Results And Raised Revenue Guidance
Kiniksa Pharmaceuticals International (KNSA) recently reported first quarter 2026 results, with revenue of US$214.27 million and net income of US$22.59 million, and raised its full year net product revenue guidance.
See our latest analysis for Kiniksa Pharmaceuticals International.
The share price has responded strongly to the Q1 2026 results and higher net product revenue guidance, with a 7 day share price return of 32.13% adding to a 37.17% year to date share price return and a 1 year total...